Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Consensus Recommendation of “Hold” by Brokerages

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) has earned a consensus rating of “Hold” from the five analysts that are currently covering the stock, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $9.50.

VRCA has been the subject of a number of research analyst reports. Brookline Capital Management restated a “hold” rating on shares of Verrica Pharmaceuticals in a report on Wednesday, October 2nd. Needham & Company LLC reissued a “hold” rating on shares of Verrica Pharmaceuticals in a research note on Tuesday, November 5th. HC Wainwright cut Verrica Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday, November 6th. Royal Bank of Canada lowered shares of Verrica Pharmaceuticals from an “outperform” rating to a “sector perform” rating and cut their price target for the stock from $11.00 to $2.00 in a report on Tuesday, November 5th. Finally, TD Cowen cut their price objective on Verrica Pharmaceuticals from $15.00 to $10.00 and set a “buy” rating on the stock in a research note on Monday, October 21st.

Institutional Trading of Verrica Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the company. Quest Partners LLC purchased a new position in shares of Verrica Pharmaceuticals during the second quarter worth approximately $50,000. Key Financial Inc bought a new position in Verrica Pharmaceuticals in the 2nd quarter valued at approximately $69,000. Rhumbline Advisers boosted its position in shares of Verrica Pharmaceuticals by 20.4% during the second quarter. Rhumbline Advisers now owns 26,591 shares of the company’s stock valued at $194,000 after buying an additional 4,514 shares during the last quarter. Barclays PLC grew its stake in shares of Verrica Pharmaceuticals by 404.6% in the third quarter. Barclays PLC now owns 31,341 shares of the company’s stock worth $45,000 after acquiring an additional 25,130 shares during the period. Finally, Renaissance Technologies LLC purchased a new stake in Verrica Pharmaceuticals during the 2nd quarter valued at $332,000. 42.45% of the stock is currently owned by hedge funds and other institutional investors.

Verrica Pharmaceuticals Price Performance

Shares of NASDAQ VRCA opened at $0.72 on Tuesday. The company has a quick ratio of 1.22, a current ratio of 1.34 and a debt-to-equity ratio of 29.58. The business’s 50 day moving average price is $1.16 and its two-hundred day moving average price is $3.74. The company has a market cap of $32.74 million, a PE ratio of -0.39 and a beta of 1.40. Verrica Pharmaceuticals has a twelve month low of $0.68 and a twelve month high of $11.41.

Verrica Pharmaceuticals (NASDAQ:VRCA) last posted its quarterly earnings results on Monday, November 4th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.12). Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 591.84%. The business had revenue of ($1.78) million during the quarter, compared to the consensus estimate of $7.53 million. On average, analysts predict that Verrica Pharmaceuticals will post -1.42 EPS for the current year.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.